| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥554.5B | ¥475.1B | +16.7% |
| Operating Income | ¥42.7B | ¥35.8B | +19.5% |
| Ordinary Income | ¥41.8B | ¥35.4B | +18.1% |
| Net Income | ¥23.5B | ¥23.5B | +0.0% |
| ROE | 16.0% | 18.8% | - |
FY2025 consolidated results: Revenue reached 55.4B yen (YoY +16.7%), Operating Income 4.3B yen (+19.5%), Ordinary Income 4.2B yen (+18.1%), and Net Income 2.8B yen (+17.5%). The company achieved both revenue and profit growth with operating margin improving to 7.7% from prior year. ROE stood at 20.5% (excluding non-controlling interests). Operating cash flow of 4.3B yen exceeded net income by 1.55x, demonstrating strong cash generation capability. Total assets expanded to 26.2B yen from 21.7B yen, driven by M&A activities including the acquisition of TMC (Vietnam) and tangible asset investments. The company announced a new medium-term plan targeting revenue of 80.0B yen, operating income of 7.5B yen, and ROE of 25.0% by 2028.
Revenue growth of +16.7% was primarily driven by three factors: (1) net addition of 260 new contracted facilities in the core CS Set business, (2) facility unit price increase of 0.4M yen through value-added services, and (3) consolidation of overseas operations (GREEN and TMC in Vietnam) contributing 2.2B yen in revenue. The domestic business generated 53.2B yen in revenue while overseas operations contributed 2.2B yen, establishing a foundation for geographic diversification.
Operating income increased +19.5%, outpacing revenue growth, indicating positive operating leverage. The operating margin improved to 7.7% from prior year levels. This margin expansion resulted from (1) absorption of fixed costs through revenue scale expansion and (2) improved business efficiency. However, gross profit margin declined 1.1pt to 21.4%, reflecting competitive pricing pressure and cost structure challenges that management has identified as a key improvement area.
The gap between operating income (4.3B yen) and ordinary income (4.2B yen) was minimal at 0.1B yen, indicating limited impact from non-operating items. Equity method investment losses of 0.05B yen and interest expenses of 0.06B yen were both immaterial relative to core operations.
The gap between ordinary income (4.2B yen) and net income (2.8B yen) of 1.4B yen (33% reduction) primarily reflects normal tax burden, with income tax expenses of 1.3B yen. No material extraordinary items or impairment losses were recorded. The company follows a pattern of revenue growth with profit growth, with operating leverage contributing to margin expansion despite gross margin pressure.
The domestic business represents the core operation, generating revenue of 53.2B yen (96% of total) and operating income of 4.0B yen with an operating margin of 7.5%. This segment drove overall revenue growth through net addition of 260 contracted facilities and facility unit price improvement of 0.4M yen. The CS Set business model demonstrates stable recurring revenue characteristics with gradual facility base expansion.
The overseas business (Vietnam operations) contributed revenue of 2.2B yen (4% of total) and operating income of 0.27B yen with a post-goodwill amortization margin of 12.1% (17.9% pre-amortization). The notably higher margin in overseas operations reflects the business model characteristics of GREEN and TMC, which operate laundry services and medical uniform businesses with differentiated cost structures. The consolidation of these entities from October 2024 established the foundation for future international expansion.
Operating profit growth of +19.5% was primarily driven by the core domestic business, which maintained stable profitability while expanding facility coverage. The overseas segment, despite its small scale, contributed positively to consolidated profitability. The margin differential between segments (7.5% domestic vs. 12.1% overseas post-amortization) suggests potential for margin improvement as the company scales both operations and potentially transfers operational best practices between geographies.
Profitability: ROE 20.5% represents a strong return level, calculated as net profit margin 5.0% × total asset turnover 2.11x × financial leverage 1.79x. Operating margin improved to 7.7% from prior year, though gross profit margin of 21.4% declined 1.1pt YoY, indicating pricing pressure and cost structure challenges. Return on assets stood at 11.5%, reflecting efficient asset utilization.
Cash Quality: OCF/Net Income ratio of 1.55x indicates earnings are well-supported by cash generation. Free cash flow of 0.9B yen remained positive after accommodating growth investments. Working capital of 7.5B yen appears appropriate for the business scale, with accounts receivable of 6.6B yen and inventory of 1.9B yen representing reasonable operating cycle metrics.
Investment: CapEx of 1.1B yen relative to depreciation of 1.2B yen yields a ratio of 0.91x, suggesting maintenance-level investment in existing operations. However, total investing cash outflow of 3.4B yen including 1.1B yen for subsidiary acquisition reflects active growth investment phase. Goodwill increased to 1.3B yen from 0.4B yen (+196.4%), and intangible assets rose to 1.8B yen from 1.0B yen (+87.4%), creating future amortization obligations and potential impairment risk.
Financial Health: Equity ratio of 56.0% (up from 57.6% prior year) remains healthy despite asset expansion. Current ratio of 168.6% and quick ratio of 151.6% indicate strong short-term liquidity. Interest-bearing debt of 0.8B yen remains modest with Debt/EBITDA of 0.14x, providing ample financial flexibility. However, short-term liabilities represent 48% of total liabilities, exceeding the 40% threshold and warranting monitoring of refinancing risk, though absolute liquidity coverage remains strong with cash of 6.8B yen covering short-term borrowings 18.7x.
Operating CF: 4.3B yen (1.55x of Net Income) demonstrates strong cash-backed earnings quality. The OCF conversion exceeding 1.0x indicates core business operations generate cash reliably. Working capital changes included increases in accounts receivable reflecting revenue growth, while the overall operating cash generation remained robust.
Investing CF: -3.4B yen primarily comprised CapEx of 1.1B yen for facility and equipment investments and 1.1B yen for subsidiary acquisition (TMC Vietnam). The company also invested in securities and other financial assets. The elevated investing cash outflow reflects the active growth investment phase, with M&A and infrastructure development to support future expansion.
Financing CF: -1.2B yen included dividend payments of 0.8B yen (payout ratio 28.5% based on dividends relative to net income). Long-term borrowings increased 0.3B yen while short-term debt decreased, suggesting refinancing toward longer maturities. No share buyback activity was recorded.
FCF: 0.9B yen (Operating CF 4.3B yen - CapEx 1.1B yen) remained positive, covering dividend payments of 0.8B yen with FCF coverage of 1.14x. The modest FCF surplus reflects active growth investment while maintaining shareholder returns.
Cash generation: Strong. The company demonstrates solid operating cash generation capability with OCF/Net Income of 1.55x, though FCF is constrained by growth investments. The cash conversion cycle appears efficient with negative accruals ratio of -5.8%, indicating revenues are well-converted to cash.
Ordinary vs Net Income: The gap between ordinary income (4.2B yen) and net income (2.8B yen) of 1.4B yen (33% reduction) is primarily attributable to normal income tax expenses of 1.3B yen, representing an effective tax rate of approximately 31%. No material non-recurring items were recorded. Equity method investment losses of 0.05B yen and minority interests of 0.4B yen had limited impact.
Non-operating income composition was immaterial relative to revenue scale. Interest expenses of 0.06B yen represent only 0.1% of revenue, confirming minimal financial cost burden. The absence of significant extraordinary gains or losses, asset impairments, or restructuring charges indicates core earnings quality is sound.
Accruals: Operating cash flow of 4.3B yen exceeding net income of 2.8B yen by 1.55x indicates negative accruals, a positive signal for earnings quality. The accruals ratio of -5.8% suggests earnings are well-supported by cash generation rather than accounting adjustments. Depreciation and amortization of 1.2B yen represents normal non-cash charges. No material concerns regarding earnings quality are evident from cash flow analysis.
Progress rate vs. full-year: Based on FY2025 results (revenue 55.4B yen, operating income 4.3B yen) against the new FY2026 forecast (revenue 60.8B yen, operating income 5.0B yen), the company projects +9.7% revenue growth and +17.0% operating income growth. The operating margin is expected to improve from 7.7% to 8.2%, indicating continued operating leverage benefits.
Management announced a new medium-term plan (2026-2028) with FY2028 targets of revenue 80.0B yen, operating income 7.5B yen (margin 9.4%), and ROE 25.0%. This represents a compound annual growth rate of approximately 10-11% for revenue and 15-16% for operating income from FY2025 base levels. Key drivers include: (1) stable CS Set business growth with focus on customer retention and unit price improvement, (2) new business development including discharge/home care sets and nursing home apparel service (Smile Wear), (3) overseas expansion leveraging the Vietnam platform, and (4) selective M&A investments of 9-12B yen allocated across domestic infrastructure strengthening, management support services, and international expansion.
The company identified ROE improvement from current 20.5% to target 25.0% as a critical management priority, establishing KPI trees linked to executive compensation. Specific initiatives include reducing customer churn rate, improving gross margin through contract redesign and procurement optimization, and maintaining capital efficiency discipline in growth investments.
Dividend policy: The company declared a year-end dividend of 13.0 yen per share (no interim dividend), resulting in an annual dividend of 13.0 yen. Based on basic EPS of 45.77 yen, the payout ratio is 28.4%. For FY2026, management forecasts a dividend of 16.0 yen per share (payout ratio 30.3% against forecast EPS of 52.81 yen), representing +23.1% YoY dividend growth.
The company established a dividend policy of maintaining payout ratio above 30% while balancing growth investments and shareholder returns. Management expressed commitment to sustainable dividend growth aligned with earnings expansion. Operating cash flow of 4.3B yen and free cash flow of 0.9B yen provide adequate coverage for dividend payments of 0.8B yen (FCF coverage 1.14x), though the modest FCF surplus reflects active growth investment prioritization.
No share buyback program was disclosed or executed in the reporting period. The total shareholder return ratio is equivalent to the dividend payout ratio of 28.4% in the absence of buybacks. Management is designing a performance-linked stock option program for directors and executives to align interests with shareholder value creation, though specific details have not been finalized.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Based on the company's 5-year historical trend, revenue growth accelerated to 16.7% in FY2025, representing strong momentum in the healthcare support services sector. The operating margin of 7.7% demonstrates improving profitability trajectory, while net profit margin of 4.2% reflects the company's position in a service-intensive business model with moderate margin characteristics.
The dividend payout ratio of 33% (normalized basis) indicates a balanced capital allocation approach between growth reinvestment and shareholder returns, appropriate for a company in active expansion phase. The company's ROE of 20.5% significantly exceeds typical cost of capital levels (management estimates 7-8%) and positions favorably within the healthcare services sector, which generally exhibits mid-to-high teen ROE ranges for efficiently managed operators.
The company's financial health metrics including equity ratio of 56.0% and minimal leverage (Debt/EBITDA 0.14x) provide substantial flexibility to execute growth strategies including M&A investments. Operating cash flow conversion of 1.55x relative to net income exceeds healthy benchmark of 1.0x, indicating business model quality.
Note: Industry comparison data is derived from proprietary analysis of publicly available financial data. Specific peer median comparisons are limited by the company's somewhat unique business model positioning in hospital/nursing home consumables and laundry services, which spans traditional medical services, business services, and rental/leasing sectors.
Customer concentration and churn risk: The CS Set business model depends on contracted facility retention, and the company has acknowledged an upward trend in customer churn rate driven by facility consolidations and competitive pricing pressure. A 1 percentage point increase in annual churn rate would materially impact recurring revenue stability. Management has prioritized churn rate reduction through enhanced value proposition (M3 collaboration) and improved service quality, but execution risk remains. Quantification: Each 1pt churn increase potentially impacts 40-50 facilities annually based on current 4,000+ facility base.
Gross margin compression and pricing power: Gross profit margin declined 1.1pt to 21.4% in FY2025, reflecting competitive dynamics and cost inflation in procurement and logistics. The company operates in a price-sensitive segment where hospital/nursing home customers face budget constraints. Further margin erosion of 0.5-1.0pt annually would pressure operating leverage and threaten the operating margin expansion trajectory toward the 9.4% FY2028 target. Management has initiated contract redesign and procurement optimization programs, but effectiveness remains to be demonstrated.
M&A execution and goodwill impairment risk: Goodwill increased 196.4% to 1.3B yen, and management plans additional M&A investments of 9-12B yen through FY2028. Historical under-delivery versus prior medium-term plan raises concerns about acquisition integration capability and return realization. If acquired businesses underperform, goodwill impairment charges could materially impact profitability. The company has implemented stricter investment criteria focused on capital efficiency (ROE hurdle rates), but track record building is required. A single large impairment of 0.5-1.0B yen would reduce net income by 20-35% from current levels.
Strong cash-backed earnings growth with margin expansion trajectory: The company demonstrated high-quality earnings growth with operating income +19.5% outpacing revenue +16.7%, while operating cash flow of 1.55x net income confirms cash generation strength. The operating margin improvement to 7.7% with a clear pathway toward 9.4% by FY2028 indicates positive operating leverage as the business scales. The combination of recurring revenue characteristics from CS Set contracts, facility base expansion, and unit price improvement creates visibility for sustained growth.
Strategic platform building for multi-pillar growth model: Management has articulated a clear transition from single-business dependency (CS Set) toward a diversified portfolio encompassing hospital management support services, overseas operations, and new business lines. The M3 collaboration leverages digital healthcare infrastructure to enhance competitive positioning and pricing power. The Vietnam platform (GREEN/TMC) establishes a foundation for Asia expansion aligned with regional aging demographics. Capital allocation of 9-12B yen for M&A with explicit ROE hurdles and KPI-linked executive compensation demonstrates capital efficiency discipline. Execution risk exists given prior plan shortfalls, but the strategy framework appears sound.
ROE-focused management with shareholder return commitment: The company's explicit ROE target of 25.0% (versus cost of capital 7-8%) and establishment of ROE-linked KPIs across the organization represent a meaningful shift toward capital efficiency culture. Current ROE of 20.5% already exceeds many sector peers, and the 4.5pt improvement target appears achievable through the combination of profit growth (operating income CAGR 15-16%), stable asset turnover, and disciplined leverage management. The commitment to 30%+ dividend payout ratio with sustainable FCF coverage balances growth reinvestment with cash returns, appropriate for a maturing growth company.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
In the fiscal year ending December 2025, the company achieved higher revenue and profit with net sales of 55.4 billion yen (+16.7% YoY) and operating profit of 4.2 billion yen (+19.5%). CS Set contracted facilities reached 2,830 (+260 facilities), and facility unit price rose to 18.8万円/month. Under the new medium-term management plan, the company targets net sales of 80.0 billion yen, operating profit of 7.5 billion yen, and ROE of 25% by 2028, anchored by “stable growth of CS Sets” and the expansion of “M&A, overseas, and hospital management support.” Emphasizing capital efficiency, it will execute growth investments with ROE 25% as a lower-bound target. The dividend payout ratio will be maintained at 30%, and operating CF of 16.0 billion yen will be allocated to growth investments of 9.0–12.0 billion yen and dividends of 3.0 billion yen.
359 new CS Set contracts (99 cancellations), facility unit price of 18.8万円/month (+0.4万円), with the recurring (stock-type) business expanding steadily. Vietnam subsidiaries (GREEN Co. and TMC Co.) posted sales of 2,234百万円 and an operating margin of 12.1% (17.9% before goodwill amortization), contributing to overseas expansion. The joint business with M3, Inc. is fully underway with 100 synergy cases realized, contributing to higher facility unit prices and lower cancellation rates. In the new medium-term plan, a lower-bound ROE target of 25% by 2028; over three years, allocate operating CF of 16.0 billion yen to growth investments including 9.0–12.0 billion yen for M&A. While recognizing capital cost at 7–8%, ROE at 20.5% exceeds this; however, the downward trend in ROE is seen as an issue, and performance-linked stock options are planned to be introduced.
For the fiscal year ending December 2026, the company plans net sales of 60.8 billion yen (+9.7%) and operating profit of 5.0 billion yen (+17.0%). It expects growth through new facility acquisitions and value enhancement for CS Sets, expansion of overseas business, and M&A. It will work on improving gross margin and reducing the cancellation rate, targeting an improvement in operating margin to 8.2%. Over the medium to long term, it aims for sustainable growth by increasing the penetration rate among hospitals and Geriatric Health Services Facilities (hospital 20.4%, nursing care 10.6%) and by rolling out small-scale facilities and new services.
Management recognizes a gap between its perceived capital cost of 7–8% and investors’ expected return of 8–9%. Viewing the downward trend in ROE as a challenge, it will tie KPIs based on the ROE tree (sales growth, gross margin, cancellation rate, etc.) to the performance accountability of executive officers and division heads, and link them with performance-linked stock options. It acknowledges that the decline in PER stems from entering a steady-growth phase, making future potential harder to discern. M&A is positioned as a key option, with an emphasis on execution focused on capital efficiency and maximizing shareholder value.
Acquire new CS Set facilities and enhance value (CS Set R and LC, original patient wear lifte, Smile Wear for nursing care facilities). Create synergies by expanding the joint business with M3, Inc. (hospital management support, new value-added services). Accelerate overseas expansion (growth of Vietnam’s GREEN Co. and TMC Co., phased rollout to other Asian countries). Advance M&A strategy (invest 9.0–12.0 billion yen across three types: domestic platform enhancement, management support, and overseas expansion). Optimize growth investment and capital allocation disciplined by ROE of 25% (allocate operating CF of 16.0 billion yen to growth investments and dividends).
Under the previous medium-term plan (2023–2025), both revenue and profit missed targets each year (revenue achievement 94–95%, operating profit 91%). Downward trend in CS Set gross margin and the manifestation of structural issues (addressed through contract redesign and review of procurement methods). Rising cancellation rate (impacted by consolidation/closures and price competition) addressed through talent retention and value creation. Short-term debt ratio of 48% (flagged in XBRL analysis) leading to refinancing risk. Significant increase in goodwill and intangible assets (goodwill expanded to 1.266 billion yen, about double) resulting in future impairment risk.